-
Enabling possibility
of life-changing cell therapies for patients with
cancer and rare genetic diseases -
Enabling possibility
of life-changing cell therapies for patients with
cancer and rare genetic diseases -
Enabling possibility
of life-changing cell therapies for patients with
cancer and rare genetic diseases
Latest News
View AllAug 06, 2019
Gamida Cell Reports Second Quarter 2019 Financial Results and Provides Company Update
Read MoreJul 23, 2019
Gamida Cell Announces the Date of Its Second Quarter 2019 Financial Results and Webcast
Read MoreJul 08, 2019
Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read MoreJun 26, 2019
Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary Shares
Read MoreJun 24, 2019
Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares
Read MoreJun 19, 2019
Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel
Read MoreJun 05, 2019
Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer
Read MoreMay 31, 2019
Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting
Read MoreMay 29, 2019
Gamida Cell to Hold Annual Meeting of Stockholders
Read MoreMay 09, 2019
Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City
Read MoreMay 07, 2019
Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update
Read MoreApr 30, 2019
Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast
Read MoreApr 22, 2019
Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
Read MoreApr 05, 2019
Gamida Cell to Present at the 18th Annual Needham Healthcare Conference
Read MoreMar 21, 2019
Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
Read MoreFeb 25, 2019
Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
Read MoreFeb 23, 2019
Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting
Read MoreFeb 21, 2019
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
Read MoreFeb 19, 2019
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
Read MoreFeb 14, 2019
Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting
Read MoreJan 24, 2019
Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
Read MoreJan 22, 2019
Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration
Read MoreJan 07, 2019
Gamida Cell Announces 2019 Goals and Provides Company Update
Read MoreDec 04, 2018
Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology
Read MoreDec 03, 2018
Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting
Read MoreNov 28, 2018
Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Read MoreNov 01, 2018
Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting
Read MoreOct 26, 2018
Gamida Cell Announces Pricing of Initial Public Offering
Read MoreSep 18, 2018
Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman
Read MoreAug 06, 2018
Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications
Read MoreJul 23, 2018
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
Read MoreJul 17, 2018
Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation
Read MoreJun 18, 2018
Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma
Read MoreApr 30, 2018
Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting
Read MoreApr 26, 2018
Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing
Read MoreMar 19, 2018
Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting
Read MoreMar 16, 2018
Gamida Cell to Present at Upcoming Investor Conferences
Read MoreMar 15, 2018
Gamida Cell Appoints Shai Lankry as Chief Financial Officer
Read MoreFeb 20, 2018
Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings
Read MoreJan 16, 2018
Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma
Read MoreDec 11, 2017
Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting
Read MoreNov 20, 2017
Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer
Read MoreNov 01, 2017
Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting
Read MoreSep 26, 2017
Gamida Cell World Cord Blood Day Conference, November 15, 2017
Read MoreAug 21, 2017
Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
Read MoreJul 10, 2017
Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
Read MoreJun 19, 2017
Gamida Cell Announces $40 Million Private Financing
Read MoreJun 05, 2017
Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors
Read MoreApr 20, 2017
Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation
Read MoreMar 23, 2017
Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord® in Haematopoietic Stem Cell Transplantation (HSCT)
Read MoreFeb 28, 2017
Gamida Cell Announces First Patient Transplanted in Phase 3 Registration Study of NiCord for Blood Cancers
Read MoreDec 06, 2016
Gamida Cell Presents Positive Data From Phase 1/2 Study of NiCord® as a Curative Treatment for Sickle Cell Disease at ASH 2016
Read MoreNov 21, 2016
Gamida Cell Names Julian Adams, Ph.D. New Chairman of the Board
Read MoreOct 11, 2016
Gamida Cell Receives FDA Breakthrough Therapy Designation For NiCord®
Read MoreSep 15, 2016
Gamida Cell Announces Appointment of Julian Adams, Ph.D.and Kenneth I. Moch to its Board of Directors
Read MoreJul 27, 2016
Gamida Cell Announces First Patient with Sickle Cell Disease Transplanted in Phase 1/2 Study of CordIn™ as the Sole Graft Source
Read MoreJun 06, 2016
Gamida Cell Presents Data From Phase 1/2 Study of NiCord® for High Risk Hematological Malignancies at ASCO 2016
Read MoreMay 23, 2016
Gamida Cell Announces $4.4 Million Grant from the Israeli Government
Read MoreApr 05, 2016
Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients at EBMT 2016
Read MoreCommitted to changing treatment paradigms
We are focused on developing advanced cell therapies as potentially curative approaches for patients with serious medical conditions who have limited treatment options.
